For the year ending 2025-12-31, VYCO had -$18,666 decrease in cash & cash equivalents over the period. -$18,695 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -72,426 |
| Depreciation of fixed assets | 63,143 |
| Allowance for doubtful accounts - accounts receivable | 2,690 |
| Stock based compensation | 48,838 |
| Accounts receivable | -23,678 |
| Inventory | 8,792 |
| Prepaid expenses | 24,363 |
| Accrued interest - related party | 35,284 |
| Accrued interest | 48,000 |
| Accounts payable | -62,813 |
| Accrued liabilities | -67,346 |
| Changes in discontinued operations, net | 636 |
| Cash (used in) provided by operating activities | -13,471 |
| Purchase of fixed assets | 5,224 |
| Sale of fixed assets | 841 |
| Cash used in investing activities | -4,383 |
| Proceeds - notes payable other | 59,024 |
| Repayments - notes payable other | 59,836 |
| Cash used in financing activities | -812 |
| Net (decrease) increase in cash | -18,666 |
| Cash at beginning of year | 105,648 |
| Cash at end of year | 86,982 |
VYCOR MEDICAL INC (VYCO)
VYCOR MEDICAL INC (VYCO)